Stockscreener 앱 받기
1.38
4.83%
-0.07
시간 외 거래:
1.34
-0.04
-2.90%
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire
Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
FATE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Growth Value: Is Fate Therapeutics Inc subject to activist investor interestQuarterly Market Summary & High Return Trade Opportunity Guides - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations - MarketBeat
Fate Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Baird reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Fate Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Fate Therapeutics: Fourth Quarter Earnings Overview - Bitget
Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027. - Bitget
FATE THERAPEUTICS INC SEC 10-K Report - TradingView
Fate Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times
Fate Therapeutics reports lower Q4 collaboration revenue - TradingView
Form 10-K FATE THERAPEUTICS INC For: Dec 31 - StreetInsider
Earnings Summary: Fate Therapeutics Q4 - Benzinga
Fate Therapeutics (NASDAQ: FATE) cuts 2025 expenses, extends cash runway - Stock Titan
Off-the-shelf CAR-T goes outpatient as Fate cuts hospital stays, chemo - Stock Titan
Fate Therapeutics FY 2025 Loss Reduction Tests Bullish Narratives On Path To Profitability - Sahm
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Bond Watch: What are AFBIs technical support levels2025 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
Aug Patterns: Will Fate Therapeutics Inc outperform small cap indexes2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Fate Therapeutics (FATE) to Release Earnings on Wednesday - MarketBeat
Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World
Aug PreEarnings: Can Roundhill Etf Trust Roundhill Aapl Weeklypay Etf reach all time highs this yearQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
Will Fate Therapeutics Inc. outperform the market in YEARTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru
Is Fate Therapeutics Inc. stock risky to hold now2025 Geopolitical Influence & Advanced Technical Signal Analysis - mfd.ru
Is Fate Therapeutics Inc. subject to activist investor interestJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru
MSN Money - MSN
Can Fate Therapeutics Inc. lead its sector in growthJuly 2025 Technicals & Fast Entry and Exit Trade Plans - mfd.ru
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GuruFocus
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times
What analysts say about Fate Therapeutics Inc. stock2025 Investor Takeaways & Community Shared Stock Ideas - mfd.ru
FATE PE Ratio & Valuation, Is FATE Overvalued - Intellectia AI
S P Trends: What analysts say about Fate Therapeutics Inc stock2025 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Gains Recap: Can Fate Therapeutics Inc lead its sector in growthMarket Movers & Community Verified Watchlist Alerts - baoquankhu1.vn
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving AverageWhat's Next? - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average – What’s Next? - Defense World
Nasdaq Moves: What is the dividend yield of Fate Therapeutics IncMarket Performance Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Loss Report: Can Fate Therapeutics Inc ride the EV waveVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
The Truth About Fate Therapeutics Inc: Is This Biotech Underdog About To Explode Or Implode? - AD HOC NEWS
Guidance Update: What analysts say about Fate Therapeutics Inc stock2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened - Defense World
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year - simplywall.st
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results - IT Business Net
Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock - Defense World
Insider Selling: Fate Therapeutics (NASDAQ:FATE) Insider Sells 10,589 Shares of Stock - MarketBeat
3.69%
0.68%
자본화:
|
볼륨(24시간):